Jin Zhang M.D., Ph.D

Both foreign and domestic pharmas are in a race to bring PD-1/PD-L1 inhibitors into China, writes Jin Zhang.

Jin Zhang provides an overview of China's major bispecific antibody developers.

In the face of booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports.

Tyrosine-kinase inhibitors (TKIs) are gradually becoming the most popular option for lung cancer treatment in China. Jin Zhang reports.

In an attempt to reduce high drug prices and improve its medical insurance coverage, China has initiated a series of new moves, including the recent zero import tax on a range of anticancer drugs. Jin Zhang reports.

With China predicted to account for 48% of the global diabetes population by 2045, Jin Zhang looks at how the country's domestic pharma companies are faring in this treatment area.

On May 1, China eliminated the tariff on 28 categories of imported drugs. Jin Zhang looks at the implications for foreign and domestic pharma companies.

The PD-1/PD-L1 market in China is heating up and companies there have made a series of advances, writes Jin Zhang.

Jin Zhang identifies the major domestic companies in China’s IVD industry.

Jin Zhang discusses the research and development of several major biologics in China.

Jin Zhang looks at how China's CART-T therapy race is heating up.

Outlining the four major areas driving China’s life sciences industry, which may be on the cusp of a new era in R&D and healthcare reform.     

Jin Zhang outlines four key areas that impacted Chinese pharma in 2017 and looks at how their effects will shape the industry in the years ahead.

Jin Zhang reviews the current fortunes of the Chinese pharmaceutical companies.